PRODUCT – Page 12

Merck Halts Two Phase 3 Trials of Keytruda for Early-Stage Lung and Skin Cancers

1 year ago talkbio0Tagged Early-stage, KEYNOTE-630, KEYNOTE-867, Keytruda, Malignant neoplasm of lung, Malignant neoplasm of skin, Merck, Phase 3 trials

Merck, Keytruda, Phase 3 trials, early-stage lung cancer, skin cancer, KEYNOTE-867, KEYNOTE-630

Johnson & Johnson’s 340B Drug Discount Policy Change Rejected by HHS

1 year ago talkbio0Tagged 340B, CHARGE Syndrome, drug discount program, HHS, hospital payments, HRSA, Johnson and Johnson, Stelara

Johnson & Johnson, 340B drug discount program, Stelara, Xarelto, HHS, HRSA, drug pricing, hospital payments

Bavarian Nordic Shares Surge on Strong Earnings and Major Mpox Vaccine Order Amid Global Health Emergency

1 year ago talkbio0Tagged Bavarian Nordic, earnings, Global Health Emergency, mpox vaccine, Report (document), Vaccines, World Health Organization

Bavarian Nordic, Mpox Vaccine, Global Health Emergency, WHO, Vaccine Order, Earnings Report

Novartis and Versant Invest $150M in Kidney Biotech Borealis to Replicate Chinook’s Success

1 year ago talkbio0Tagged Borealis, Chronic Kidney Diseases, Investments, Kidney, Novartis, Versant

Novartis, Versant, Borealis, kidney biotech, $150M investment, Chinook Therapeutics, chronic kidney disease, biotech funding

Bavarian Nordic Ramps Up Mpox Vaccine Production to Combat Global Health Emergency

1 year ago talkbio0Tagged Africa, Bavarian Nordic, Centers for Disease Control and Prevention (U.S.), Global Health Emergency, Jynneos, mpox vaccine, World Health Organization

Bavarian Nordic, Mpox Vaccine, Jynneos, Global Health Emergency, Africa CDC, WHO

FDA Grants Tentative Approval for YUTREPIA, a New Treatment for Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease

1 year ago talkbio0Tagged Associated with, Lung Diseases, Interstitial, PH-ILD, Pulmonary arterial hypertension, Pulmonary Hypertension, regulatory exclusivity, Tentative Approval, Tyvaso, United States Food and Drug Administration, United Therapeutics, YUTREPIA

YUTREPIA, treprostinil, pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), FDA tentative approval, regulatory exclusivity, United Therapeutics, Tyvaso

Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events

1 year ago talkbio0Tagged Adverse event, amgen, Antibodies, Bispecific, CAR-T, Carvykti, China, Curon Biopharmaceutical, Evaluation procedure, File (record), Legend Biotech, Merck, United States Food and Drug Administration

Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti